Pancreatic cancer: Advances and challenges

CJ Halbrook, CA Lyssiotis, MP di Magliano, A Maitra - Cell, 2023 - cell.com
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers. Significant
efforts have largely defined major genetic factors driving PDAC pathogenesis and …

Evaluation and management of neuroendocrine tumors of the pancreas

AT Scott, JR Howe - Surgical Clinics, 2019 - surgical.theclinics.com
Neuroendocrine tumors (NETs) are a diverse group of neoplasms arising from cells in the
diffuse neuroendocrine system. At least 17 different types of neuroendocrine cells are found …

ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine …

M Falconi, B Eriksson, G Kaltsas, DK Bartsch… - …, 2016 - karger.com
Only advances that occurred from 2011 to 2014 that either strengthen the previous 2011
guidelines [1, 2] or lead to changes or additional guidelines are reviewed here. Advances …

Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors

I Marinoni, AS Kurrer, E Vassella, M Dettmer… - Gastroenterology, 2014 - Elsevier
Background & Aims Sporadic pancreatic neuroendocrine tumors (pNETs) are rare and
genetically heterogeneous. Chromosome instability (CIN) has been detected in pNETs from …

A cross-species analysis in pancreatic neuroendocrine tumors reveals molecular subtypes with distinctive clinical, metastatic, developmental, and metabolic …

A Sadanandam, S Wullschleger, CA Lyssiotis… - Cancer discovery, 2015 - AACR
Seeking to assess the representative and instructive value of an engineered mouse model
of pancreatic neuroendocrine tumors (PanNET) for its cognate human cancer, we profiled …

Neoplasms of the neuroendocrine pancreas: an update in the classification, definition, and molecular genetic advances

JM Guilmette, V Nosé - Advances in anatomic pathology, 2019 - journals.lww.com
This review focuses on discussing the main modifications of the recently published 2017
WHO Classification of Neoplasms of the Neuroendocrine Pancreas (panNEN). Recent …

Apelin inhibition prevents resistance and metastasis associated with anti‐angiogenic therapy

I Uribesalgo, D Hoffmann, Y Zhang… - EMBO molecular …, 2019 - embopress.org
Angiogenesis is a hallmark of cancer, promoting growth and metastasis. Anti‐angiogenic
treatment has limited efficacy due to therapy‐induced blood vessel alterations, often …

A clinicopathologic and molecular update of pancreatic neuroendocrine neoplasms with a focus on the new World Health Organization classification

JM Fang, J Shi - Archives of pathology & laboratory …, 2019 - meridian.allenpress.com
Context.—According to the 2017 World Health Organization classification, pancreatic
neuroendocrine neoplasms (PanNENs) include a new category of pancreatic …

[HTML][HTML] Update on pancreatic neuroendocrine tumors

LR McKenna, BH Edil - Gland surgery, 2014 - ncbi.nlm.nih.gov
Pancreatic neuroendocrine tumors (pNETs) are relatively rare tumors comprising 1-2% of all
pancreas neoplasms. In the last 10 years our understanding of this disease has increased …

The role of ATRX in the alternative lengthening of telomeres (ALT) phenotype

JP Amorim, G Santos, J Vinagre, P Soares - Genes, 2016 - mdpi.com
Telomeres are responsible for protecting chromosome ends in order to prevent the loss of
coding DNA. Their maintenance is required for achieving immortality by neoplastic cells and …